An earlier readout from rival Pfizer Inc. PFE — which has a first interim analysis with lower events — could prompt savvy investors to buy the dip in Moderna shares, the analyst said. Since an emergency use authorization has never been granted by the FDA in the vaccine space before, safety will be paramount, followed by the logistical and technical risk mitigation, he said. This could prove positive for Moderna, even if it cedes the first-to-market advantage to Pfizer, as Moderna has validated manufacturing and logistics in its favor, Singh said.